Montefiore Medical Center | GenomeWeb

Montefiore Medical Center

Teams from France and Germany disputed the notion that the 21-gene signature is needed to identify low-risk breast cancer patients who can be spared chemotherapy.

Researchers used the 21-gene expression assay to find individuals at lowest risk of breast cancer recurrence, who were spared adjuvant chemotherapy.

The funding will support work identifying the mechanisms underlying the differential responses among pediatric and adult ALL patients to therapy.

The patent application was filed by Montefiore Medical Center's Sanjay Goel and John Mariadason, who discovered the association between mutations in the PIK3CA and PTEN genes and a lack of response to EGFR inhibitors.

The technology from Montefiore Medical Center relates to tumor-specific mutations in the genes PIK3CA and PTEN that can be useful in predicting patient non-response to EGFR inhibitors.

People in the News

Premium

Stephane Perrey, Kazuo Tokushige, Allen Bombard, Jorge Leon

People in the News

Premium

Frank Witney, Allen Bombard

In Science this week: genetic target for urothelial bladder cancer treatment, and more.

At the Conversation, the University of Oxford's Michael Macklay writes that learning genetic risk of disease is a personal decision.

Two dozen scientific organizations have endorsed the March for Science, according to ScienceInsider.

Researchers in Japan describe a chimpanzee with a chromosomal abnormality similar to human Down syndrome, Mashable reports.